ArticleDrug design, development and therapy2026
The Effect of Dexmedetomidine on Postoperative Acute Kidney Injury in High-Risk Partial Nephrectomy Patients: A Retrospective Cohort Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Randomized controlled trial has shown that dexmedetomidine does not significantly reduce postoperative acute kidney injury (AKI) in general partial nephrectomy (PN) populations. However, evidence remains limited in patients with high susceptibility to renal ischemia, such as those with a solitary kidney or pre-existing chronic kidney disease (CKD). Methods: We conducted a single-center retrospective cohort study including adult high-risk PN patients between 2015 and 2023. Eligible high-risk patients were those with a solitary kidney or pre-existing CKD. The study cohort was divided into dexmedetomidine-exposed and non-exposed groups. To balance baseline characteristics, inverse probability of treatment weighting (IPTW) was applied. The primary outcome was AKI incidence within 24 hours postoperatively, defined by KDIGO creatinine criteria. Results: The study included 274 patients, with 82 assigned to the dexmedetomidine-exposed cohort and 192 to the non-exposed cohort. After IPTW adjustment, all baseline covariates were well balanced. Dexmedetomidine exposure was associated with significantly lower AKI incidence (23.9% versus 38.6%, P = 0.025), with a trend toward milder AKI staging. Intraoperative urine output was higher in the dexmedetomidine group (341 ± 183 versus 282 ± 188 mL, P = 0.022). Length of postoperative hospital stay, postoperative complications, ICU admission rate, percentage decrease in eGFR from baseline at 6-month follow-up, and incidence of a >20% decrease from baseline eGFR at 6-month follow-up did not differ significantly between the two groups. Conclusion: In high-risk PN patients with a solitary kidney or pre-existing CKD, intraoperative dexmedetomidine was associated with a clinically meaningful reduction in postoperative AKI. These findings suggest a potential renoprotective role of dexmedetomidine in this vulnerable surgical population, although this early renal benefit did not translate into long-term improvements in renal function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.